# OnCo record breast-her2-positive (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/breast-her2-positive/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "breast-her2-positive" ;
  schema:name "HER2-positive breast cancer"@en ;
  schema:description "HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."@en ;
  schema:url <https://onco.cc/cancers/breast-her2-positive/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/HER2-positive_breast_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/HER2-positive_breast_cancer> ;
  onco:tag "breast", "spike" ;
  onco:related <https://onco.cc/roadmaps/adc-generations/>, <https://onco.cc/pairings/tucatinib-triplet-brain-mets/>, <https://onco.cc/pairings/pet-adapted-her2-deescalation/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/her2-low-metastatic-breast-cancer/>, <https://onco.cc/cancers/inflammatory-breast-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/her2-pet/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/cdk46-inhibitor/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/technologies/site-specific-conjugation/>, <https://onco.cc/technologies/mrd-testing/> ;
  onco:targets <https://onco.cc/targets/her2/>, <https://onco.cc/targets/cdk4-6/>, <https://onco.cc/targets/her3/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/her2-testing-assays/>, <https://onco.cc/drugs/epirubicin/>, <https://onco.cc/drugs/zanidatamab-zovodotin/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/hengrui/>, <https://onco.cc/companies/systimmune/>, <https://onco.cc/companies/johnson-johnson/>, <https://onco.cc/companies/jazz/>, <https://onco.cc/companies/zymeworks/>, <https://onco.cc/companies/puma-biotechnology/>, <https://onco.cc/companies/macrogenics/>, <https://onco.cc/companies/remegen/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/breast-cancer-signalling/>, <https://onco.cc/pathways/p53-cell-cycle/> ;
  onco:terms <https://onco.cc/terms/dual-her2-blockade/>, <https://onco.cc/terms/her2-brain-metastases/>, <https://onco.cc/terms/trastuzumab-cardiotoxicity/>, <https://onco.cc/terms/biosimilar/>, <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/ild/>, <https://onco.cc/terms/adc-sequencing/> ;
  onco:trials <https://onco.cc/trials/hera-b31-n9831/>, <https://onco.cc/trials/cleopatra/>, <https://onco.cc/trials/aphinity/>, <https://onco.cc/trials/katherine/>, <https://onco.cc/trials/destiny-breast05/>, <https://onco.cc/trials/her2climb/>, <https://onco.cc/trials/her2climb-02/>, <https://onco.cc/trials/her2climb-05/>, <https://onco.cc/trials/destiny-breast12/>, <https://onco.cc/trials/phergain/>, <https://onco.cc/trials/persephone/>, <https://onco.cc/trials/apt-trial/>, <https://onco.cc/trials/horizon-breast01/>, <https://onco.cc/trials/ace-breast-02/>, <https://onco.cc/trials/destiny-breast03/>, <https://onco.cc/trials/destiny-breast09/>, <https://onco.cc/trials/destiny-breast11/>, <https://onco.cc/trials/tmist/>, <https://onco.cc/trials/nct07003074/>, <https://onco.cc/trials/nct07008976/>, <https://onco.cc/trials/nct07043725/>, <https://onco.cc/trials/nct05838066/>, <https://onco.cc/trials/nct07441460/>, <https://onco.cc/trials/nct06747338/>, <https://onco.cc/trials/nct06846437/>, <https://onco.cc/trials/nct07377643/>, <https://onco.cc/trials/nct06968585/>, <https://onco.cc/trials/nct05346224/>, <https://onco.cc/trials/nct07386938/>, <https://onco.cc/trials/nct07413939/>, <https://onco.cc/trials/nct07673029/>, <https://onco.cc/trials/start-b/>, <https://onco.cc/trials/import-low/>, <https://onco.cc/trials/nsabp-b39/>, <https://onco.cc/trials/eortc-22922/>, <https://onco.cc/trials/ma-20/>, <https://onco.cc/trials/dbcg-82bc/>, <https://onco.cc/trials/nct06313086/>, <https://onco.cc/trials/nct07518173/>, <https://onco.cc/trials/nct06435429/>, <https://onco.cc/trials/nct06830889/>, <https://onco.cc/trials/nct06316531/>, <https://onco.cc/trials/nct07196774/>, <https://onco.cc/trials/nct06891833/>, <https://onco.cc/trials/nct05802225/>, <https://onco.cc/trials/nct07294508/>, <https://onco.cc/trials/nct06057610/>, <https://onco.cc/trials/nct04208178/>, <https://onco.cc/trials/nct04873362/>, <https://onco.cc/trials/nct07047365/>, <https://onco.cc/trials/nct06126640/>, <https://onco.cc/trials/nct06957886/>, <https://onco.cc/trials/nct05950945/>, <https://onco.cc/trials/nct05894239/>, <https://onco.cc/trials/atempt/>, <https://onco.cc/trials/nala/>, <https://onco.cc/trials/patina/>, <https://onco.cc/trials/tuxedo-1/> ;
  onco:journals <https://onco.cc/journals/breast-cancer-jbcs/>, <https://onco.cc/journals/breast-cancer-research/>, <https://onco.cc/journals/breast-cancer-research-and-treatment/>, <https://onco.cc/journals/clinical-breast-cancer/>, <https://onco.cc/journals/journal-of-mammary-gland-biology-and-neoplasia/>, <https://onco.cc/journals/the-breast/>, <https://onco.cc/journals/the-breast-journal/> ;
  onco:pipeline <https://onco.cc/technologies/her2-pet/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/disitamab-vedotin/>, <https://onco.cc/drugs/tqb2102/>, <https://onco.cc/drugs/hb1801/>, <https://onco.cc/drugs/jskn003/>, <https://onco.cc/drugs/kn026/>, <https://onco.cc/drugs/ibi354/>, <https://onco.cc/drugs/a166/>, <https://onco.cc/drugs/evorpacept/>, <https://onco.cc/drugs/hlx11/>, <https://onco.cc/drugs/rph-051/>, <https://onco.cc/drugs/ro7771950/>, <https://onco.cc/drugs/gq1005/>, <https://onco.cc/drugs/trastuzumab-rezetecan/>, <https://onco.cc/drugs/trastuzumab-brengitecan/>, <https://onco.cc/drugs/arx788/>, <https://onco.cc/trials/her2climb-05/>, <https://onco.cc/trials/horizon-breast01/>, <https://onco.cc/trials/phergain/>, <https://onco.cc/ideas/idea-tdxd-first-then-nothing/>, <https://onco.cc/ideas/idea-cns-first-adc-strategy/>, <https://onco.cc/ideas/idea-her2-adc-sequencing-payload/>, <https://onco.cc/drugs/inavolisib/>, <https://onco.cc/technologies/mrd-testing/> ;
  onco:standardOfCare <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/trastuzumab-emtansine/>, <https://onco.cc/trials/destiny-breast11/>, <https://onco.cc/trials/destiny-breast09/>, <https://onco.cc/drugs/tucatinib/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/trials/apt-trial/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/trastuzumab-emtansine/>, <https://onco.cc/trials/destiny-breast11/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/trials/phergain/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/trials/aphinity/>, <https://onco.cc/trials/hera-b31-n9831/>, <https://onco.cc/trials/destiny-breast05/>, <https://onco.cc/trials/katherine/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/trastuzumab-emtansine/>, <https://onco.cc/drugs/neratinib/>, <https://onco.cc/trials/aphinity/>, <https://onco.cc/trials/persephone/>, <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/trials/destiny-breast09/>, <https://onco.cc/trials/cleopatra/>, <https://onco.cc/trials/her2climb-05/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/drugs/tucatinib/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/trials/destiny-breast03/>, <https://onco.cc/trials/her2climb/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/tucatinib/>, <https://onco.cc/drugs/trastuzumab-emtansine/>, <https://onco.cc/drugs/neratinib/>, <https://onco.cc/drugs/lapatinib/>, <https://onco.cc/drugs/margetuximab/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/trastuzumab-rezetecan/>, <https://onco.cc/drugs/disitamab-vedotin/>, <https://onco.cc/trials/her2climb/>, <https://onco.cc/trials/destiny-breast12/>, <https://onco.cc/drugs/tucatinib/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/trials/persephone/> .